ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.
CHICAGO — Isatuximab combined with a standard first-line treatment regimen significantly reduced the risk for disease progression and death in certain older individuals with multiple myeloma, results from a randomized phase 3 study showed.Additionally, patients with newly diagnosed, transplant-ineligible disease treated in the isatuximab (Sarclisa, Sanofi) arm of the IMROZ trial had
ASCO 2024 to Highlight Art and Science of Cancer Care ajmc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ajmc.com Daily Mail and Mail on Sunday newspapers.